Is there a need for liver disease monitoring in HIV patients in Africa?

abstract：BACKGROUND:A significant proportion of hepatitis C patients treated with unmodified interferon plus ribavirin fail to respond. The optimal therapy for these patients has not been established yet. The objective of this study was to assess the efficacy and safety of peginterferon plus ribavirin with or without amantidine...

journal_title：Antiviral therapy

authors： Hasan F,Al-Khaldi J,Asker H,Al-Ajmi M,Owayed S,Varghese R,Siddique I,Al-Nakib B

更新日期：2004-08-01 00:00:00

abstract：:Oseltamivir phosphate is an FDA-approved treatment for influenza that has been available for prescription use in the USA since 1999. The present report describes findings from a post-marketing safety study of skin reactions associated with oseltamivir use. All patients in the claims-derived Ingenix Research Database w...

journal_title：Antiviral therapy

authors： Nordstrom BL,Oh K,Sacks ST,L'Italien GJ

更新日期：2004-04-01 00:00:00

abstract：OBJECTIVE:To assess the impact of nucleoside analogue reverse transcriptase inhibitor (NRTI) combination therapy on muscle and liver lactate metabolism in HIV-infected patients. METHODS:This cross-sectional study involved HIV-infected patients who were either antiretroviral-naive (Group 1) or were receiving either a s...

journal_title：Antiviral therapy

authors： Ghosn J,Guiguet M,Jardel C,Benyaou R,Zeller V,Simon A,Valantin MA,Amellal B,Assoumo L,Hogrel JY,Costagliola D,Katlama C,Lombès A

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:Increasing efavirenz (EFV) dose from 600 mg to 800 mg daily has been suggested with concomitant rifampicin (RFN), as induction of cytochrome P450 isoenzymes may reduce EFV plasma concentrations. METHODS:Individuals from the CIPRA-South Africa cohort taking EFV-based antiretroviral therapy with concomitant t...

journal_title：Antiviral therapy

authors： Orrell C,Cohen K,Conradie F,Zeinecker J,Ive P,Sanne I,Wood R

更新日期：2011-01-01 00:00:00

abstract：:Treatment of primary human immunodeficiency virus (HIV) infection (PHI) may provide an opportunity to achieve a long lasting suppression of viral replication. Although there is growing evidence of the benefit of treating PHI, clinical data are still very limited. Special therapeutic considerations in this clinical set...

journal_title：Antiviral therapy

authors： Zala C,Salomón H,Cahn P

更新日期：1999-01-01 00:00:00

abstract：:P-glycoprotein (P-gp) limits bioavailability and accumulation of HIV protease inhibitors (PIs). PIs are ligands for the pregnane-X-receptor (PXR), which regulates P-gp expression. This occurs when ligands activate the receptor, initiating binding to response elements in the MDR1 promoter. PXR also activates cytochrome...

journal_title：Antiviral therapy

authors： Owen A,Chandler B,Back DJ,Khoo SH

更新日期：2004-10-01 00:00:00

abstract：BACKGROUND:This study aimed to evaluate whether low darunavir (DRV) minimum plasma concentration (Cmin) values contribute to virological outcomes during DRV/ritonavir monotherapy (mtDRV/rtv). METHODS:This was a prospective observational single-arm 96-week efficacy study in virologically suppressed subjects on triple t...

journal_title：Antiviral therapy

authors： Gutierrez-Valencia A,Torres-Cornejo A,BenMarzouk-Hidalgo OJ,Ruiz-Valderas R,Lluch A,Viciana P,López-Cortés LF

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:The H275Y neuraminidase mutation conferring oseltamivir resistance has been reported in several pandemic A/H1N1 (pH1N1) isolates. We sought to evaluate transmission of this mutant virus through the direct contact and the airborne (aerosol and droplet) routes in the ferret model. METHODS:Groups of four ferre...

journal_title：Antiviral therapy

authors： Hamelin ME,Baz M,Bouhy X,Beaulieu E,Dubé K,Mallett C,Boivin G

更新日期：2011-01-01 00:00:00

abstract：:Active pharmaceutical ingredients (APIs) are the molecular entities that exert the therapeutic effects of medicines. This article provides an overview of the major APIs that are entered into antiretroviral therapy (ART), outlines how APIs are manufactured, and examines the regulatory and cost frameworks of manufacturi...

journal_title：Antiviral therapy

authors： Fortunak JM,de Souza RO,Kulkarni AA,King CL,Ellison T,Miranda LS

更新日期：2014-01-01 00:00:00

abstract：BACKGROUND:Few data are available about efficacy and durability of simplification from multi-tablet antiretroviral regimens to co-formulated efavirenz (EFV)/emtricitabine (FTC)/tenofovir (TDF) versus rilpivirine (RPV)/FTC/TDF in virologically suppressed HIV-1-infected patients. METHODS:We retrospectively analysed HIV-...

journal_title：Antiviral therapy

authors： Gagliardini R,Bandera A,Zaccarelli M,Sterrantino G,Latini A,D'Avino A,Lapadula G,Antinori A,Cauda R,De Luca A,Gori A,Di Giambenedetto S,Fabbiani M

更新日期：2018-01-01 00:00:00

abstract：BACKGROUND:Alterations in endogenous nucleotide pools as a result of HIV therapy with nucleoside and nucleotide reverse transcriptase inhibitors (N[t]RTIs) is a proposed mechanism for therapy-related adverse events and drug interactions resulting in treatment failure. In vitro studies were performed in order to underst...

journal_title：Antiviral therapy

authors： Vela JE,Miller MD,Rhodes GR,Ray AS

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The combination of pegylated interferon (PEG-IFN) plus ribavirin (RBV) is the standard of care for hepatitis C virus (HCV) treatment in HIV-coinfected individuals. In 2007, abacavir (ABC)-based antiretroviral therapy was, for the first time, reported to be associated with early virological failure during HCV...

journal_title：Antiviral therapy

authors： Laufer N,Laguno M,Perez I,Cifuentes C,Murillas J,Vidal F,Bonet L,Veloso S,Gatell JM,Mallolas J

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:The World Health Organization recommends HBV-HIV-coinfected individuals start antiretroviral therapy containing tenofovir. Here we describe first-line tenofovir use and treatment outcomes in coinfected patients in Asia. METHODS:HBV surface antigen positive patients enrolled in the TREAT Asia HIV Observation...

journal_title：Antiviral therapy

authors： Boettiger DC,Kerr S,Ditangco R,Chaiwarith R,Li PC,Merati TP,Pham TT,Kiertiburanakul S,Kumarasamy N,Vonthanak S,Lee CK,Van Kinh N,Pujari S,Wong WW,Kamarulzaman A,Zhang F,Yunihastuti E,Choi JY,Oka S,Ng OT,Kantipong

更新日期：2016-01-01 00:00:00

abstract：BACKGROUND:The multidrug resistance proteins (MRPs) form a subfamily within the ATP binding cassette transporters that confer resistance to a variety of structurally unrelated compounds. MRP4 has been reported to transport antiretroviral drugs out of cells in an active process. Although the main therapeutic effects of ...

journal_title：Antiviral therapy

authors： Clemente MI,Alvarez S,Serramía MJ,Turriziani O,Genebat M,Leal M,Fresno M,Muñoz-Fernández MA

更新日期：2009-01-01 00:00:00

abstract：:Chronic hepatitis C affects approximately 170 million people worldwide and is one of the leading causes of liver-related morbidity and mortality. Until 2011, the only therapeutic option was combination therapy of pegylated interferon and ribavirin, with efficacy rates around 50% and plenty of side effects. In the past...

journal_title：Antiviral therapy

authors： Calle Serrano B,Manns MP

更新日期：2012-01-01 00:00:00

abstract：:The hepatitis C virus (HCV) NS3 protein contains a serine proteinase domain implicated in the maturation of the viral polyprotein. NS3 forms a stable heterodimer with NS4A, a viral membrane protein that acts as an activator of the NS3 proteinase. The three-dimensional structure of the NS3 proteinase complexed with an ...

journal_title：Antiviral therapy

authors： De Francesco R,Pessi A,Steinkühler C

更新日期：1998-01-01 00:00:00

abstract：BACKGROUND:Clinical utilization of genotype resistance testing is evolving. We examined the extent to which HIV care providers requesting genotype resistance tests used the information appropriately and the impact of inappropriate utilization. METHODS:Data from a prospective cohort of HIV-infected patients (the HIV Ou...

journal_title：Antiviral therapy

authors： Uy J,Brooks JT,Baker R,Hoffman M,Moorman A,Novak R,HOPS Investigators.

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Pegylated interferon/ribavirin combination is currently the standard treatment for chronic hepatitis C virus (HCV) infection. Body weight adjustment of ribavirin is crucial for response. However, previous studies found no relation between ingested dose and plasma concentration. The aim of this study was to d...

journal_title：Antiviral therapy

authors： Maynard M,Pradat P,Gagnieu MC,Souvignet C,Trepo C

更新日期：2008-01-01 00:00:00

abstract：:Intravenous ribavirin was provided non-selectively for investigational open-label use among persons with suspected hantavirus pulmonary syndrome (HPS) in the United States between 4 June 1993 and 1 September 1994. Therapy was initiated prior to laboratory confirmation of hantavirus infection because most deaths from H...

journal_title：Antiviral therapy

authors： Chapman LE,Mertz GJ,Peters CJ,Jolson HM,Khan AS,Ksiazek TG,Koster FT,Baum KF,Rollin PE,Pavia AT,Holman RC,Christenson JC,Rubin PJ,Behrman RE,Bell LJ,Simpson GL,Sadek RF

更新日期：1999-01-01 00:00:00

abstract：BACKGROUND:Among 141 HIV-HBV-coinfected patients treated with tenofovir in our centre, 87% were good-responders to therapy. Seven patients showed a delayed response to tenofovir. The present study was performed to evaluate the quasispecies variability and the in vitro drug susceptibility to approved antiviral drugs of ...

journal_title：Antiviral therapy

authors： Lada O,Gervais A,Branger M,Peytavin G,Roquebert B,Collin G,Fraqueiro G,Moucari R,Leclerc L,Martinot-Peignoux M,Matheron S,Marcellin P

更新日期：2012-01-01 00:00:00

abstract：BACKGROUND:Unique serum anti-E1E2 antibodies were shown to be associated with spontaneous recovery or predictive of sustained virological response (SVR) in patients with chronic hepatitis C receiving pegylated interferon/ribavirin (PEG-IFN/RBV) therapy. The objectives were to establish the relationship between pretreat...

journal_title：Antiviral therapy

authors： Arnaud C,Pradat P,Spaziante M,Berthillon P,Maynard M,Taliani G,Chemin I,Trépo C,Petit MA

更新日期：2013-01-01 00:00:00

abstract：BACKGROUND:This study aimed to examine the evolution of genotypic drug resistance prevalence in treatment-failing patients in the multicentre, Italian, Antiretroviral Resistance Cohort Analysis (ARCA). METHODS:Patients with a drug resistance genotype test performed between 1999 and 2006 at failure of a combination ant...

journal_title：Antiviral therapy

authors： Di Giambenedetto S,Zazzi M,Corsi P,Gonnelli A,Di Pietro M,Giacometti A,Almi P,Trezzi M,Boeri E,Gianotti N,Menzo S,Del Gobbo R,Francisci D,Nerli A,Galli L,De Luca A,Antiretroviral Resistance Cohort Analysis Study Group.

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:IL28B genotype predicts response to treatment against HCV with pegylated interferon/ribavirin (PR) and impacts on the outcome of therapy including telaprevir (TVR). This study aimed to determine the influence of the favourable IL28B genotype on early viral kinetics during therapy with TVR/PR in HIV-HCV-coinf...

journal_title：Antiviral therapy

authors： Neukam K,Munteanu D,Haubitz S,Mira JA,Ingiliz P,Rivero-Juárez A,Lutz T,de los Santos-Gil I,Scholten S,Márquez M,Rauch A,Rockstroh JK,Pineda JA

更新日期：2015-01-01 00:00:00

abstract：BACKGROUND:Strong hepatitis C virus (HCV)-specific T-cell responses are associated with spontaneous clearance of acute hepatitis C. However, recent studies described a decline in HCV-specific CD8+ T-cells during interferon treatment, suggesting that the success of acute HCV therapy might be independent of adaptive immu...

journal_title：Antiviral therapy

authors： Wiegand J,Cornberg M,Aslan N,Schlaphoff V,Sarrazin C,Kubitschke A,Buggisch P,Ciner A,Jaeckel E,Manns MP,Wedemeyer H

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Drug efflux (for example, P-glycoprotein [P-gp], multidrug resistance-associated proteins [MRPs] and breast cancer resistance protein [BCRP]) and influx (for example, human organic anion transporting polypeptide [hOCTP] or human organic anion transporting polypeptide [hOATP]) transporters alter the cellular ...

journal_title：Antiviral therapy

authors： Janneh O,Anwar T,Jungbauer C,Kopp S,Khoo SH,Back DJ,Chiba P

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Once-daily dosing of abacavir and lamivudine has been approved for adults, but paediatric data are insufficient. We conducted a pharmacokinetic study of once-daily and twice-daily abacavir and lamivudine in children aged 3-<36 months. METHODS:Children with stable HIV type-1 (HIV-1) RNA levels after 12 weeks...

journal_title：Antiviral therapy

authors： Paediatric European Network for Treatment of AIDS (PENTA).

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Monocytes transmigrating to the brain play a central role in HIV neuropathology. We hypothesized that the continued existence of neurocognitive impairment (NCI) despite potent antiretroviral (ARV) therapy is mediated by the inability of such therapy to control this monocyte/macrophage reservoir. METHODS:Cro...

journal_title：Antiviral therapy

authors： Shikuma CM,Nakamoto B,Shiramizu B,Liang CY,DeGruttola V,Bennett K,Paul R,Kallianpur K,Chow D,Gavegnano C,Hurwitz SJ,Schinazi RF,Valcour VG

更新日期：2012-01-01 00:00:00

abstract：:Although chronic HBV infection is the leading cause of chronic liver disease and death worldwide, there are substantial differences in its clinical courses regarding prevalence, mode of transmission, characteristics of each phase, responses to antiviral therapy, and development of cirrhosis and hepatocellular carcinom...

journal_title：Antiviral therapy

authors： Kim BK,Revill PA,Ahn SH

更新日期：2011-01-01 00:00:00

abstract：:In order to study the inhibitory effect of various reverse transcriptase inhibitors (RTIs) on cell-free HIV, we adapted a recently described in vitro system, based on co-cultures of dendritic cells and resting CD4 T cells, modelling early target cells during sexual transmission. The compounds tested included the secon...

journal_title：Antiviral therapy

authors： Njai HF,Lewi PJ,Janssen CG,Garcia S,Fransen K,Kestens L,Vanham G,Janssen PA

更新日期：2005-01-01 00:00:00

abstract：:Drug resistance is an expected consequence of antiviral therapy for chronic hepatitis B because of the high rate of hepatitis B virus (HBV) replication, the lack of proof-reading during reverse transcription of the pregenomic RNA and the low efficacy of available therapies in eliminating covalently closed circular HBV...

journal_title：Antiviral therapy

authors： Fung SK,Lok AS

更新日期：2004-12-01 00:00:00